AR045951A1 - Inhibidores de cetp y sus metabolitos - Google Patents

Inhibidores de cetp y sus metabolitos

Info

Publication number
AR045951A1
AR045951A1 ARP040103515A ARP040103515A AR045951A1 AR 045951 A1 AR045951 A1 AR 045951A1 AR P040103515 A ARP040103515 A AR P040103515A AR P040103515 A ARP040103515 A AR P040103515A AR 045951 A1 AR045951 A1 AR 045951A1
Authority
AR
Argentina
Prior art keywords
ch2ch3
ch2co2h
co2ch3
ch2ch2oh
inhibitors
Prior art date
Application number
ARP040103515A
Other languages
English (en)
Original Assignee
Pfizer Hospital Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Hospital Prod filed Critical Pfizer Hospital Prod
Publication of AR045951A1 publication Critical patent/AR045951A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
    • C07C309/15—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton the nitrogen atom of at least one of the amino groups being part of any of the groups, X being a hetero atom, Y being any atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/08—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Los compuestos que resultan de la administración de torcetrapib a un mamífero, y el uso de tales compuestos como un indicador o marcador biológico para la presencia o exposición de torcetrapib en el plasma de un mamífero, incluidos los humanos. La presente también está dirigida a los inhibidores de la proteína de transferencia de ésteres de colesterilo (siglas en inglés, CETP), composiciones farmacéuticas que contienen tales inhibidores y el uso de tales inhibidores para elevar determinados niveles plasmáticos de lípidos, incluyendo el colesterol de lipoproteínas de alta densidad (HDL) y para disminuir determinados niveles plasmáticos de lípidos diferentes, tales como el colesterol de lipoproteínas de baja densidad (LDL) y los triglicéridos. Reivindicación 1: Un compuesto que tiene la fórmula (1) en el que R1 es -CO2CH3 o -H; R2 es -CH2CH3, -CH2CH2OH, -CH2CO2H, -CH2CO2A, y -CH2CH2OA, en el que A es el ácido 3,4,5-trihidroxi-tetrahidropiran-2-carboxílico; y R3 es -H, - CO2CH2CH3, -CO2CH2CH2CH, -CO2CH2CO2H, -CO2CH2CH2OA y -CO2CH2CO2A; o una sal farmacéuticamente aceptable de dicho compuesto con la condición de que si R1 es -COCH3 y R3 es -H, entonces R2 no es -CH2CH3, -CH2CH2OH, o -CH2CO2H; si R1 es -CO2CH3 y R3 es -CO2CH2CH3, entonces R2 no es -CH2CH3, -CH2CH2OH, o -CH2CO2H; y si R1 es -CO2CH3 y R2 es -CH2CH3, entonces R3 no es -CO2CH2CH2OH, o -CO2CH2CO2H.
ARP040103515A 2003-09-30 2004-09-28 Inhibidores de cetp y sus metabolitos AR045951A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50738503P 2003-09-30 2003-09-30

Publications (1)

Publication Number Publication Date
AR045951A1 true AR045951A1 (es) 2005-11-16

Family

ID=34421617

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040103515A AR045951A1 (es) 2003-09-30 2004-09-28 Inhibidores de cetp y sus metabolitos

Country Status (9)

Country Link
US (1) US20070004774A1 (es)
EP (1) EP1670765A2 (es)
JP (1) JP2007507481A (es)
AR (1) AR045951A1 (es)
BR (1) BRPI0414671A (es)
CA (1) CA2540231A1 (es)
MX (1) MXPA06003499A (es)
TW (1) TW200511993A (es)
WO (1) WO2005033082A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1670768T1 (sl) 2003-10-08 2010-01-29 Lilly Co Eli Spojine in metode za zdravljenje dislipidemije
WO2006033004A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Quinoline compounds as cetp inhibitors
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
ATE550326T1 (de) * 2006-07-31 2012-04-15 Cadila Healthcare Ltd Als modulatoren von hdl einsetzbare verbindungen
EP2918578A1 (en) 2007-03-16 2015-09-16 Concert Pharmaceuticals, Inc. Inhibitors of cholesterol ester transfer protein
AU2012202172B2 (en) * 2007-11-05 2013-08-29 Novartis Ag 4-benzylamino-1-carboxyacyl-piperidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis
PT2207775E (pt) 2007-11-05 2012-05-11 Novartis Ag Derivados de 4-benzilamino-1-carboxiacil-piperidina como inibidores de cetp úteis para o tratamento de doenças tais como hiperlipidemia ou arteriosclerose
ES2425776T3 (es) 2007-12-03 2013-10-17 Novartis Ag Derivados 1,2-disustituidos de 4-bencilamino-pirrolidina como inhibidores CETP útiles para el tratamiento de enfermedades tales como hiperlipidemia o arteriosclerosis
WO2010075069A1 (en) 2008-12-16 2010-07-01 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
WO2012101142A1 (en) 2011-01-26 2012-08-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for assessing a subject's risk of having a cardiovascular disease.
CN111004177A (zh) * 2019-12-26 2020-04-14 河南省科学院高新技术研究中心 一种1-羟乙基-2,2,4-三甲基-1,2,3,4-四氢喹啉的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
IL158765A0 (en) * 2001-06-21 2004-05-12 Pfizer Prod Inc Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof

Also Published As

Publication number Publication date
TW200511993A (en) 2005-04-01
MXPA06003499A (es) 2006-06-08
WO2005033082A2 (en) 2005-04-14
BRPI0414671A (pt) 2006-11-21
WO2005033082A3 (en) 2005-06-16
US20070004774A1 (en) 2007-01-04
EP1670765A2 (en) 2006-06-21
CA2540231A1 (en) 2005-04-14
JP2007507481A (ja) 2007-03-29

Similar Documents

Publication Publication Date Title
AR021481A1 (es) Compuestos de 1,2,3,4-tetrahidroquinolinas 2-sustituidas 4-carboxiamino sustituidas, uso para la preparacion de medicamentos, composiciones y kit que lo contiene
AR045951A1 (es) Inhibidores de cetp y sus metabolitos
PA8481201A1 (es) 1,2,3,4-tetrahidroquinolinas 2-sustituidas 4-amino
AR109789A2 (es) Compuestos lipídicos
Liu et al. 25-Hydroxycholesterol activates the expression of cholesterol 25-hydroxylase in an LXR-dependent mechanism [S]
CL2021000645A1 (es) Métodos para reducir el riesgo de eventos cardiovasculares en un sujeto.
ES2539861T3 (es) Formulaciones en emulsión de clevidipina que contienen agentes antimicrobianos
UY29222A1 (es) Compuestos y derivados de dibencil amina
ECSP056040A (es) 1,2, 4 SUSTITUIDO 1,2,3,4-TETRAHIDRO Y 1,2, DIHIDRO-QUINOLINA y 1,2,3,4-TETRADHIDRO-QUINOXALINA-DERIVADOS COMO INHIBIDORES CETP PARA EL TRATAMIENTO DE ATEROSCLEROSIS Y OBESIDAD
CL2011002268A1 (es) Uso de compuestos derivados de acidos grasos poliinsaturados para el tratamiento de enfermedades neurodegenerativas y neurologicas; y composicion farmaceutica o nutraceutica.
PT1626728E (pt) Lipidos oxidados e sua utilização no tratamento de doenças e desordens inflamatórias
GT200300021A (es) Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
BRPI1014572B8 (pt) Imidazopirazinas para uso como inibidores de cinase
UY28369A1 (es) Agentes terapéuticos
AR074391A1 (es) Composicion farmaceutica de un potente inhibidor de hcv para su administracion oral
NI200800227A (es) Acidos 1,3-dioxano carboxilicos
AR042131A1 (es) Compuestos de piperidina fenil sustituidas y su uso como activadores de ppar
AR083772A1 (es) Metodos de tratamiento con compuestos de lipidos
AR074854A1 (es) Compuestos de plasmalogenos, composiciones farmaceuticas que los comprenden, su uso para tratar enfermedades del envejecimiento, procedimiento e intermediarios para su sintesis.
AR055090A1 (es) Una presentacion farmaceutica de forma de dosificacion de liberacion modificada que comprende un inhibidor de la enzima ciclooxigenasa
Yamashita et al. Extrinsic plasmalogens suppress neuronal apoptosis in mouse neuroblastoma Neuro-2A cells: importance of plasmalogen molecular species
BR112014032525A2 (pt) composição de resina para toner, toner, revelador e aparelho de formação de imagem
Cao et al. Promoting intestinal lymphatic transport targets a liver-X receptor (LXR) agonist (WAY-252,623) to lymphocytes and enhances immunomodulation
AR080228A1 (es) Derivados de piridina triciclicos medicamentos que contienen tales compuestos su uso y proceso para su preparacion
Kobayashi et al. Dietary supplementation with eicosapentaenoic acid inhibits plasma cell differentiation and attenuates lupus autoimmunity

Legal Events

Date Code Title Description
FB Suspension of granting procedure